Global Autoimmune Gastrointestinal Dysmotility Market Growth 2022-2028
The global market for Autoimmune Gastrointestinal Dysmotility is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Autoimmune Gastrointestinal Dysmotility market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Autoimmune Gastrointestinal Dysmotility market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Autoimmune Gastrointestinal Dysmotility market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Autoimmune Gastrointestinal Dysmotility market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Autoimmune Gastrointestinal Dysmotility players cover Ycellbio Medical Co.， Ltd, Zimmer Biomet, Stryker Corporation, Regen Lab S.A and ROCKY MOUNTAIN BIOLOGICALS, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Autoimmune Gastrointestinal Dysmotility market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Autoimmune Gastrointestinal Dysmotility market, with both quantitative and qualitative data, to help readers understand how the Autoimmune Gastrointestinal Dysmotility market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Autoimmune Gastrointestinal Dysmotility market and forecasts the market size by Type (Plasma Exchange, Medications and Immunotherapy), by Application (Hospital, Specialist Clinic and Other,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Plasma Exchange
Medications
Immunotherapy
Segmentation by application
Hospital
Specialist Clinic
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Ycellbio Medical Co.， Ltd
Zimmer Biomet
Stryker Corporation
Regen Lab S.A
ROCKY MOUNTAIN BIOLOGICALS
TERUMO BCT, INC
GLOFINN
ExaTech Inc
EmCyte Corporation
ThermoGenesis Holdings, Inc
Octapharma Brasil Ltda
Dr PRP USA LLC
Isto Biologics
Arthrex, Inc
Terumo Corporation
Cascade Medical
Grifols, S.A
Chapter Introduction
Chapter 1: Scope of Autoimmune Gastrointestinal Dysmotility, Research Methodology, etc.
Chapter 2: Executive Summary, global Autoimmune Gastrointestinal Dysmotility market size (sales and revenue) and CAGR, Autoimmune Gastrointestinal Dysmotility market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Autoimmune Gastrointestinal Dysmotility sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Autoimmune Gastrointestinal Dysmotility sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Autoimmune Gastrointestinal Dysmotility market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Ycellbio Medical Co.， Ltd, Zimmer Biomet, Stryker Corporation, Regen Lab S.A, ROCKY MOUNTAIN BIOLOGICALS, TERUMO BCT, INC, GLOFINN, ExaTech Inc and EmCyte Corporation, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Autoimmune Gastrointestinal Dysmotility Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Autoimmune Gastrointestinal Dysmotility by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Autoimmune Gastrointestinal Dysmotility by Country/Region, 2017, 2022 & 2028
2.2 Autoimmune Gastrointestinal Dysmotility Segment by Type
2.2.1 Plasma Exchange
2.2.2 Medications
2.2.3 Immunotherapy
2.3 Autoimmune Gastrointestinal Dysmotility Sales by Type
2.3.1 Global Autoimmune Gastrointestinal Dysmotility Sales Market Share by Type (2017-2022)
2.3.2 Global Autoimmune Gastrointestinal Dysmotility Revenue and Market Share by Type (2017-2022)
2.3.3 Global Autoimmune Gastrointestinal Dysmotility Sale Price by Type (2017-2022)
2.4 Autoimmune Gastrointestinal Dysmotility Segment by Application
2.4.1 Hospital
2.4.2 Specialist Clinic
2.4.3 Other
2.5 Autoimmune Gastrointestinal Dysmotility Sales by Application
2.5.1 Global Autoimmune Gastrointestinal Dysmotility Sale Market Share by Application (2017-2022)
2.5.2 Global Autoimmune Gastrointestinal Dysmotility Revenue and Market Share by Application (2017-2022)
2.5.3 Global Autoimmune Gastrointestinal Dysmotility Sale Price by Application (2017-2022)
3 Global Autoimmune Gastrointestinal Dysmotility by Company
3.1 Global Autoimmune Gastrointestinal Dysmotility Breakdown Data by Company
3.1.1 Global Autoimmune Gastrointestinal Dysmotility Annual Sales by Company (2020-2022)
3.1.2 Global Autoimmune Gastrointestinal Dysmotility Sales Market Share by Company (2020-2022)
3.2 Global Autoimmune Gastrointestinal Dysmotility Annual Revenue by Company (2020-2022)
3.2.1 Global Autoimmune Gastrointestinal Dysmotility Revenue by Company (2020-2022)
3.2.2 Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Company (2020-2022)
3.3 Global Autoimmune Gastrointestinal Dysmotility Sale Price by Company
3.4 Key Manufacturers Autoimmune Gastrointestinal Dysmotility Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Autoimmune Gastrointestinal Dysmotility Product Location Distribution
3.4.2 Players Autoimmune Gastrointestinal Dysmotility Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Autoimmune Gastrointestinal Dysmotility by Geographic Region
4.1 World Historic Autoimmune Gastrointestinal Dysmotility Market Size by Geographic Region (2017-2022)
4.1.1 Global Autoimmune Gastrointestinal Dysmotility Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Autoimmune Gastrointestinal Dysmotility Annual Revenue by Geographic Region
4.2 World Historic Autoimmune Gastrointestinal Dysmotility Market Size by Country/Region (2017-2022)
4.2.1 Global Autoimmune Gastrointestinal Dysmotility Annual Sales by Country/Region (2017-2022)
4.2.2 Global Autoimmune Gastrointestinal Dysmotility Annual Revenue by Country/Region
4.3 Americas Autoimmune Gastrointestinal Dysmotility Sales Growth
4.4 APAC Autoimmune Gastrointestinal Dysmotility Sales Growth
4.5 Europe Autoimmune Gastrointestinal Dysmotility Sales Growth
4.6 Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales Growth
5 Americas
5.1 Americas Autoimmune Gastrointestinal Dysmotility Sales by Country
5.1.1 Americas Autoimmune Gastrointestinal Dysmotility Sales by Country (2017-2022)
5.1.2 Americas Autoimmune Gastrointestinal Dysmotility Revenue by Country (2017-2022)
5.2 Americas Autoimmune Gastrointestinal Dysmotility Sales by Type
5.3 Americas Autoimmune Gastrointestinal Dysmotility Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Autoimmune Gastrointestinal Dysmotility Sales by Region
6.1.1 APAC Autoimmune Gastrointestinal Dysmotility Sales by Region (2017-2022)
6.1.2 APAC Autoimmune Gastrointestinal Dysmotility Revenue by Region (2017-2022)
6.2 APAC Autoimmune Gastrointestinal Dysmotility Sales by Type
6.3 APAC Autoimmune Gastrointestinal Dysmotility Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Autoimmune Gastrointestinal Dysmotility by Country
7.1.1 Europe Autoimmune Gastrointestinal Dysmotility Sales by Country (2017-2022)
7.1.2 Europe Autoimmune Gastrointestinal Dysmotility Revenue by Country (2017-2022)
7.2 Europe Autoimmune Gastrointestinal Dysmotility Sales by Type
7.3 Europe Autoimmune Gastrointestinal Dysmotility Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Autoimmune Gastrointestinal Dysmotility by Country
8.1.1 Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales by Country (2017-2022)
8.1.2 Middle East & Africa Autoimmune Gastrointestinal Dysmotility Revenue by Country (2017-2022)
8.2 Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales by Type
8.3 Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Autoimmune Gastrointestinal Dysmotility
10.3 Manufacturing Process Analysis of Autoimmune Gastrointestinal Dysmotility
10.4 Industry Chain Structure of Autoimmune Gastrointestinal Dysmotility
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Autoimmune Gastrointestinal Dysmotility Distributors
11.3 Autoimmune Gastrointestinal Dysmotility Customer
12 World Forecast Review for Autoimmune Gastrointestinal Dysmotility by Geographic Region
12.1 Global Autoimmune Gastrointestinal Dysmotility Market Size Forecast by Region
12.1.1 Global Autoimmune Gastrointestinal Dysmotility Forecast by Region (2023-2028)
12.1.2 Global Autoimmune Gastrointestinal Dysmotility Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Autoimmune Gastrointestinal Dysmotility Forecast by Type
12.7 Global Autoimmune Gastrointestinal Dysmotility Forecast by Application
13 Key Players Analysis
13.1 Ycellbio Medical Co.， Ltd
13.1.1 Ycellbio Medical Co.， Ltd Company Information
13.1.2 Ycellbio Medical Co.， Ltd Autoimmune Gastrointestinal Dysmotility Product Offered
13.1.3 Ycellbio Medical Co.， Ltd Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Ycellbio Medical Co.， Ltd Main Business Overview
13.1.5 Ycellbio Medical Co.， Ltd Latest Developments
13.2 Zimmer Biomet
13.2.1 Zimmer Biomet Company Information
13.2.2 Zimmer Biomet Autoimmune Gastrointestinal Dysmotility Product Offered
13.2.3 Zimmer Biomet Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Zimmer Biomet Main Business Overview
13.2.5 Zimmer Biomet Latest Developments
13.3 Stryker Corporation
13.3.1 Stryker Corporation Company Information
13.3.2 Stryker Corporation Autoimmune Gastrointestinal Dysmotility Product Offered
13.3.3 Stryker Corporation Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Stryker Corporation Main Business Overview
13.3.5 Stryker Corporation Latest Developments
13.4 Regen Lab S.A
13.4.1 Regen Lab S.A Company Information
13.4.2 Regen Lab S.A Autoimmune Gastrointestinal Dysmotility Product Offered
13.4.3 Regen Lab S.A Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Regen Lab S.A Main Business Overview
13.4.5 Regen Lab S.A Latest Developments
13.5 ROCKY MOUNTAIN BIOLOGICALS
13.5.1 ROCKY MOUNTAIN BIOLOGICALS Company Information
13.5.2 ROCKY MOUNTAIN BIOLOGICALS Autoimmune Gastrointestinal Dysmotility Product Offered
13.5.3 ROCKY MOUNTAIN BIOLOGICALS Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 ROCKY MOUNTAIN BIOLOGICALS Main Business Overview
13.5.5 ROCKY MOUNTAIN BIOLOGICALS Latest Developments
13.6 TERUMO BCT, INC
13.6.1 TERUMO BCT, INC Company Information
13.6.2 TERUMO BCT, INC Autoimmune Gastrointestinal Dysmotility Product Offered
13.6.3 TERUMO BCT, INC Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 TERUMO BCT, INC Main Business Overview
13.6.5 TERUMO BCT, INC Latest Developments
13.7 GLOFINN
13.7.1 GLOFINN Company Information
13.7.2 GLOFINN Autoimmune Gastrointestinal Dysmotility Product Offered
13.7.3 GLOFINN Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 GLOFINN Main Business Overview
13.7.5 GLOFINN Latest Developments
13.8 ExaTech Inc
13.8.1 ExaTech Inc Company Information
13.8.2 ExaTech Inc Autoimmune Gastrointestinal Dysmotility Product Offered
13.8.3 ExaTech Inc Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 ExaTech Inc Main Business Overview
13.8.5 ExaTech Inc Latest Developments
13.9 EmCyte Corporation
13.9.1 EmCyte Corporation Company Information
13.9.2 EmCyte Corporation Autoimmune Gastrointestinal Dysmotility Product Offered
13.9.3 EmCyte Corporation Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 EmCyte Corporation Main Business Overview
13.9.5 EmCyte Corporation Latest Developments
13.10 ThermoGenesis Holdings, Inc
13.10.1 ThermoGenesis Holdings, Inc Company Information
13.10.2 ThermoGenesis Holdings, Inc Autoimmune Gastrointestinal Dysmotility Product Offered
13.10.3 ThermoGenesis Holdings, Inc Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 ThermoGenesis Holdings, Inc Main Business Overview
13.10.5 ThermoGenesis Holdings, Inc Latest Developments
13.11 Octapharma Brasil Ltda
13.11.1 Octapharma Brasil Ltda Company Information
13.11.2 Octapharma Brasil Ltda Autoimmune Gastrointestinal Dysmotility Product Offered
13.11.3 Octapharma Brasil Ltda Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Octapharma Brasil Ltda Main Business Overview
13.11.5 Octapharma Brasil Ltda Latest Developments
13.12 Dr PRP USA LLC
13.12.1 Dr PRP USA LLC Company Information
13.12.2 Dr PRP USA LLC Autoimmune Gastrointestinal Dysmotility Product Offered
13.12.3 Dr PRP USA LLC Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Dr PRP USA LLC Main Business Overview
13.12.5 Dr PRP USA LLC Latest Developments
13.13 Isto Biologics
13.13.1 Isto Biologics Company Information
13.13.2 Isto Biologics Autoimmune Gastrointestinal Dysmotility Product Offered
13.13.3 Isto Biologics Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Isto Biologics Main Business Overview
13.13.5 Isto Biologics Latest Developments
13.14 Arthrex, Inc
13.14.1 Arthrex, Inc Company Information
13.14.2 Arthrex, Inc Autoimmune Gastrointestinal Dysmotility Product Offered
13.14.3 Arthrex, Inc Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Arthrex, Inc Main Business Overview
13.14.5 Arthrex, Inc Latest Developments
13.15 Terumo Corporation
13.15.1 Terumo Corporation Company Information
13.15.2 Terumo Corporation Autoimmune Gastrointestinal Dysmotility Product Offered
13.15.3 Terumo Corporation Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Terumo Corporation Main Business Overview
13.15.5 Terumo Corporation Latest Developments
13.16 Cascade Medical
13.16.1 Cascade Medical Company Information
13.16.2 Cascade Medical Autoimmune Gastrointestinal Dysmotility Product Offered
13.16.3 Cascade Medical Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Cascade Medical Main Business Overview
13.16.5 Cascade Medical Latest Developments
13.17 Grifols, S.A
13.17.1 Grifols, S.A Company Information
13.17.2 Grifols, S.A Autoimmune Gastrointestinal Dysmotility Product Offered
13.17.3 Grifols, S.A Autoimmune Gastrointestinal Dysmotility Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 Grifols, S.A Main Business Overview
13.17.5 Grifols, S.A Latest Developments
14 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Autoimmune Gastrointestinal Dysmotility Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Autoimmune Gastrointestinal Dysmotility Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Plasma Exchange
Table 4. Major Players of Medications
Table 5. Major Players of Immunotherapy
Table 6. Global Autoimmune Gastrointestinal Dysmotility Sales by Type (2017-2022) & (K Units)
Table 7. Global Autoimmune Gastrointestinal Dysmotility Sales Market Share by Type (2017-2022)
Table 8. Global Autoimmune Gastrointestinal Dysmotility Revenue by Type (2017-2022) & ($ million)
Table 9. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Type (2017-2022)
Table 10. Global Autoimmune Gastrointestinal Dysmotility Sale Price by Type (2017-2022) & (US$/Unit)
Table 11. Global Autoimmune Gastrointestinal Dysmotility Sales by Application (2017-2022) & (K Units)
Table 12. Global Autoimmune Gastrointestinal Dysmotility Sales Market Share by Application (2017-2022)
Table 13. Global Autoimmune Gastrointestinal Dysmotility Revenue by Application (2017-2022)
Table 14. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Application (2017-2022)
Table 15. Global Autoimmune Gastrointestinal Dysmotility Sale Price by Application (2017-2022) & (US$/Unit)
Table 16. Global Autoimmune Gastrointestinal Dysmotility Sales by Company (2020-2022) & (K Units)
Table 17. Global Autoimmune Gastrointestinal Dysmotility Sales Market Share by Company (2020-2022)
Table 18. Global Autoimmune Gastrointestinal Dysmotility Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Company (2020-2022)
Table 20. Global Autoimmune Gastrointestinal Dysmotility Sale Price by Company (2020-2022) & (US$/Unit)
Table 21. Key Manufacturers Autoimmune Gastrointestinal Dysmotility Producing Area Distribution and Sales Area
Table 22. Players Autoimmune Gastrointestinal Dysmotility Products Offered
Table 23. Autoimmune Gastrointestinal Dysmotility Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Autoimmune Gastrointestinal Dysmotility Sales by Geographic Region (2017-2022) & (K Units)
Table 27. Global Autoimmune Gastrointestinal Dysmotility Sales Market Share Geographic Region (2017-2022)
Table 28. Global Autoimmune Gastrointestinal Dysmotility Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Autoimmune Gastrointestinal Dysmotility Sales by Country/Region (2017-2022) & (K Units)
Table 31. Global Autoimmune Gastrointestinal Dysmotility Sales Market Share by Country/Region (2017-2022)
Table 32. Global Autoimmune Gastrointestinal Dysmotility Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Autoimmune Gastrointestinal Dysmotility Sales by Country (2017-2022) & (K Units)
Table 35. Americas Autoimmune Gastrointestinal Dysmotility Sales Market Share by Country (2017-2022)
Table 36. Americas Autoimmune Gastrointestinal Dysmotility Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Country (2017-2022)
Table 38. Americas Autoimmune Gastrointestinal Dysmotility Sales by Type (2017-2022) & (K Units)
Table 39. Americas Autoimmune Gastrointestinal Dysmotility Sales Market Share by Type (2017-2022)
Table 40. Americas Autoimmune Gastrointestinal Dysmotility Sales by Application (2017-2022) & (K Units)
Table 41. Americas Autoimmune Gastrointestinal Dysmotility Sales Market Share by Application (2017-2022)
Table 42. APAC Autoimmune Gastrointestinal Dysmotility Sales by Region (2017-2022) & (K Units)
Table 43. APAC Autoimmune Gastrointestinal Dysmotility Sales Market Share by Region (2017-2022)
Table 44. APAC Autoimmune Gastrointestinal Dysmotility Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Region (2017-2022)
Table 46. APAC Autoimmune Gastrointestinal Dysmotility Sales by Type (2017-2022) & (K Units)
Table 47. APAC Autoimmune Gastrointestinal Dysmotility Sales Market Share by Type (2017-2022)
Table 48. APAC Autoimmune Gastrointestinal Dysmotility Sales by Application (2017-2022) & (K Units)
Table 49. APAC Autoimmune Gastrointestinal Dysmotility Sales Market Share by Application (2017-2022)
Table 50. Europe Autoimmune Gastrointestinal Dysmotility Sales by Country (2017-2022) & (K Units)
Table 51. Europe Autoimmune Gastrointestinal Dysmotility Sales Market Share by Country (2017-2022)
Table 52. Europe Autoimmune Gastrointestinal Dysmotility Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Country (2017-2022)
Table 54. Europe Autoimmune Gastrointestinal Dysmotility Sales by Type (2017-2022) & (K Units)
Table 55. Europe Autoimmune Gastrointestinal Dysmotility Sales Market Share by Type (2017-2022)
Table 56. Europe Autoimmune Gastrointestinal Dysmotility Sales by Application (2017-2022) & (K Units)
Table 57. Europe Autoimmune Gastrointestinal Dysmotility Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales by Country (2017-2022) & (K Units)
Table 59. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales by Type (2017-2022) & (K Units)
Table 63. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales by Application (2017-2022) & (K Units)
Table 65. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Autoimmune Gastrointestinal Dysmotility
Table 67. Key Market Challenges & Risks of Autoimmune Gastrointestinal Dysmotility
Table 68. Key Industry Trends of Autoimmune Gastrointestinal Dysmotility
Table 69. Autoimmune Gastrointestinal Dysmotility Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Autoimmune Gastrointestinal Dysmotility Distributors List
Table 72. Autoimmune Gastrointestinal Dysmotility Customer List
Table 73. Global Autoimmune Gastrointestinal Dysmotility Sales Forecast by Region (2023-2028) & (K Units)
Table 74. Global Autoimmune Gastrointestinal Dysmotility Sales Market Forecast by Region
Table 75. Global Autoimmune Gastrointestinal Dysmotility Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Autoimmune Gastrointestinal Dysmotility Sales Forecast by Country (2023-2028) & (K Units)
Table 78. Americas Autoimmune Gastrointestinal Dysmotility Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Autoimmune Gastrointestinal Dysmotility Sales Forecast by Region (2023-2028) & (K Units)
Table 80. APAC Autoimmune Gastrointestinal Dysmotility Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Autoimmune Gastrointestinal Dysmotility Sales Forecast by Country (2023-2028) & (K Units)
Table 82. Europe Autoimmune Gastrointestinal Dysmotility Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Autoimmune Gastrointestinal Dysmotility Sales Forecast by Type (2023-2028) & (K Units)
Table 86. Global Autoimmune Gastrointestinal Dysmotility Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Autoimmune Gastrointestinal Dysmotility Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Autoimmune Gastrointestinal Dysmotility Sales Forecast by Application (2023-2028) & (K Units)
Table 90. Global Autoimmune Gastrointestinal Dysmotility Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Autoimmune Gastrointestinal Dysmotility Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share Forecast by Application (2023-2028)
Table 93. Ycellbio Medical Co.， Ltd Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 94. Ycellbio Medical Co.， Ltd Autoimmune Gastrointestinal Dysmotility Product Offered
Table 95. Ycellbio Medical Co.， Ltd Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 96. Ycellbio Medical Co.， Ltd Main Business
Table 97. Ycellbio Medical Co.， Ltd Latest Developments
Table 98. Zimmer Biomet Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 99. Zimmer Biomet Autoimmune Gastrointestinal Dysmotility Product Offered
Table 100. Zimmer Biomet Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 101. Zimmer Biomet Main Business
Table 102. Zimmer Biomet Latest Developments
Table 103. Stryker Corporation Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 104. Stryker Corporation Autoimmune Gastrointestinal Dysmotility Product Offered
Table 105. Stryker Corporation Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 106. Stryker Corporation Main Business
Table 107. Stryker Corporation Latest Developments
Table 108. Regen Lab S.A Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 109. Regen Lab S.A Autoimmune Gastrointestinal Dysmotility Product Offered
Table 110. Regen Lab S.A Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 111. Regen Lab S.A Main Business
Table 112. Regen Lab S.A Latest Developments
Table 113. ROCKY MOUNTAIN BIOLOGICALS Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 114. ROCKY MOUNTAIN BIOLOGICALS Autoimmune Gastrointestinal Dysmotility Product Offered
Table 115. ROCKY MOUNTAIN BIOLOGICALS Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 116. ROCKY MOUNTAIN BIOLOGICALS Main Business
Table 117. ROCKY MOUNTAIN BIOLOGICALS Latest Developments
Table 118. TERUMO BCT, INC Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 119. TERUMO BCT, INC Autoimmune Gastrointestinal Dysmotility Product Offered
Table 120. TERUMO BCT, INC Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 121. TERUMO BCT, INC Main Business
Table 122. TERUMO BCT, INC Latest Developments
Table 123. GLOFINN Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 124. GLOFINN Autoimmune Gastrointestinal Dysmotility Product Offered
Table 125. GLOFINN Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 126. GLOFINN Main Business
Table 127. GLOFINN Latest Developments
Table 128. ExaTech Inc Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 129. ExaTech Inc Autoimmune Gastrointestinal Dysmotility Product Offered
Table 130. ExaTech Inc Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 131. ExaTech Inc Main Business
Table 132. ExaTech Inc Latest Developments
Table 133. EmCyte Corporation Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 134. EmCyte Corporation Autoimmune Gastrointestinal Dysmotility Product Offered
Table 135. EmCyte Corporation Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 136. EmCyte Corporation Main Business
Table 137. EmCyte Corporation Latest Developments
Table 138. ThermoGenesis Holdings, Inc Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 139. ThermoGenesis Holdings, Inc Autoimmune Gastrointestinal Dysmotility Product Offered
Table 140. ThermoGenesis Holdings, Inc Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 141. ThermoGenesis Holdings, Inc Main Business
Table 142. ThermoGenesis Holdings, Inc Latest Developments
Table 143. Octapharma Brasil Ltda Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 144. Octapharma Brasil Ltda Autoimmune Gastrointestinal Dysmotility Product Offered
Table 145. Octapharma Brasil Ltda Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 146. Octapharma Brasil Ltda Main Business
Table 147. Octapharma Brasil Ltda Latest Developments
Table 148. Dr PRP USA LLC Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 149. Dr PRP USA LLC Autoimmune Gastrointestinal Dysmotility Product Offered
Table 150. Dr PRP USA LLC Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 151. Dr PRP USA LLC Main Business
Table 152. Dr PRP USA LLC Latest Developments
Table 153. Isto Biologics Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 154. Isto Biologics Autoimmune Gastrointestinal Dysmotility Product Offered
Table 155. Isto Biologics Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 156. Isto Biologics Main Business
Table 157. Isto Biologics Latest Developments
Table 158. Arthrex, Inc Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 159. Arthrex, Inc Autoimmune Gastrointestinal Dysmotility Product Offered
Table 160. Arthrex, Inc Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 161. Arthrex, Inc Main Business
Table 162. Arthrex, Inc Latest Developments
Table 163. Terumo Corporation Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 164. Terumo Corporation Autoimmune Gastrointestinal Dysmotility Product Offered
Table 165. Terumo Corporation Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 166. Terumo Corporation Main Business
Table 167. Terumo Corporation Latest Developments
Table 168. Cascade Medical Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 169. Cascade Medical Autoimmune Gastrointestinal Dysmotility Product Offered
Table 170. Cascade Medical Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 171. Cascade Medical Main Business
Table 172. Cascade Medical Latest Developments
Table 173. Grifols, S.A Basic Information, Autoimmune Gastrointestinal Dysmotility Manufacturing Base, Sales Area and Its Competitors
Table 174. Grifols, S.A Autoimmune Gastrointestinal Dysmotility Product Offered
Table 175. Grifols, S.A Autoimmune Gastrointestinal Dysmotility Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 176. Grifols, S.A Main Business
Table 177. Grifols, S.A Latest Developments
List of Figures
Figure 1. Picture of Autoimmune Gastrointestinal Dysmotility
Figure 2. Autoimmune Gastrointestinal Dysmotility Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Autoimmune Gastrointestinal Dysmotility Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Autoimmune Gastrointestinal Dysmotility Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Autoimmune Gastrointestinal Dysmotility Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Plasma Exchange
Figure 10. Product Picture of Medications
Figure 11. Product Picture of Immunotherapy
Figure 12. Global Autoimmune Gastrointestinal Dysmotility Sales Market Share by Type in 2021
Figure 13. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Type (2017-2022)
Figure 14. Autoimmune Gastrointestinal Dysmotility Consumed in Hospital
Figure 15. Global Autoimmune Gastrointestinal Dysmotility Market: Hospital (2017-2022) & (K Units)
Figure 16. Autoimmune Gastrointestinal Dysmotility Consumed in Specialist Clinic
Figure 17. Global Autoimmune Gastrointestinal Dysmotility Market: Specialist Clinic (2017-2022) & (K Units)
Figure 18. Autoimmune Gastrointestinal Dysmotility Consumed in Other
Figure 19. Global Autoimmune Gastrointestinal Dysmotility Market: Other (2017-2022) & (K Units)
Figure 20. Global Autoimmune Gastrointestinal Dysmotility Sales Market Share by Application (2017-2022)
Figure 21. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Application in 2021
Figure 22. Autoimmune Gastrointestinal Dysmotility Revenue Market by Company in 2021 ($ Million)
Figure 23. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Company in 2021
Figure 24. Global Autoimmune Gastrointestinal Dysmotility Sales Market Share by Geographic Region (2017-2022)
Figure 25. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Geographic Region in 2021
Figure 26. Global Autoimmune Gastrointestinal Dysmotility Sales Market Share by Region (2017-2022)
Figure 27. Global Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Country/Region in 2021
Figure 28. Americas Autoimmune Gastrointestinal Dysmotility Sales 2017-2022 (K Units)
Figure 29. Americas Autoimmune Gastrointestinal Dysmotility Revenue 2017-2022 ($ Millions)
Figure 30. APAC Autoimmune Gastrointestinal Dysmotility Sales 2017-2022 (K Units)
Figure 31. APAC Autoimmune Gastrointestinal Dysmotility Revenue 2017-2022 ($ Millions)
Figure 32. Europe Autoimmune Gastrointestinal Dysmotility Sales 2017-2022 (K Units)
Figure 33. Europe Autoimmune Gastrointestinal Dysmotility Revenue 2017-2022 ($ Millions)
Figure 34. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales 2017-2022 (K Units)
Figure 35. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Revenue 2017-2022 ($ Millions)
Figure 36. Americas Autoimmune Gastrointestinal Dysmotility Sales Market Share by Country in 2021
Figure 37. Americas Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Country in 2021
Figure 38. United States Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 39. Canada Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 40. Mexico Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 41. Brazil Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 42. APAC Autoimmune Gastrointestinal Dysmotility Sales Market Share by Region in 2021
Figure 43. APAC Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Regions in 2021
Figure 44. China Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 45. Japan Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 46. South Korea Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 47. Southeast Asia Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 48. India Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 49. Australia Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 50. Europe Autoimmune Gastrointestinal Dysmotility Sales Market Share by Country in 2021
Figure 51. Europe Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Country in 2021
Figure 52. Germany Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 53. France Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 54. UK Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 55. Italy Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 56. Russia Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 57. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Sales Market Share by Country in 2021
Figure 58. Middle East & Africa Autoimmune Gastrointestinal Dysmotility Revenue Market Share by Country in 2021
Figure 59. Egypt Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 60. South Africa Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 61. Israel Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 62. Turkey Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 63. GCC Country Autoimmune Gastrointestinal Dysmotility Revenue Growth 2017-2022 ($ Millions)
Figure 64. Manufacturing Cost Structure Analysis of Autoimmune Gastrointestinal Dysmotility in 2021
Figure 65. Manufacturing Process Analysis of Autoimmune Gastrointestinal Dysmotility
Figure 66. Industry Chain Structure of Autoimmune Gastrointestinal Dysmotility
Figure 67. Channels of Distribution
Figure 68. Distributors Profiles
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets